Abstract
The emergence and diffusion of various types of health care technologies over the last two decades has been characterized by unprecedented vigor in development and proliferation. The degree to which such interventions have been embraced in the ‘rational’ health care environment of developed countries is hardly less than astonishing, given that the great majority have received little or no examination to scientific standards, which might demonstrate benefits or risks to health.
Chapter PDF
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
Keywords
- Prostate Cancer
- Benign Prostatic Hyperplasia
- Health Technology Assessment
- Critical Inquiry
- Prostate Cancer Incidence
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Anderson, K.M., Odell, P.M., Wilson, P.W.F., & Kannel, W.B. (1990). Cardiovascular disease risk profiles. American Heart Journal, 121, 293–8.
Barlow, D., Cooper, C., Reeve, J., & Reid, D. (1996, February). Department of health is fair to patients with osteoporosis. British Medical Journal, 312, 297–8.
Bassett, K. (1996). Anthropology, clinical pathology and the electronic fetal monitor: Lessons from the heart. Social Science and Medicine, 42(2), 281–92.
Bassett, K., & Kazanjian, A. (1996). Incorporating clinical effectiveness debates into hospital technology assessment: The case of laser treatment of benign prostatic hyperplasia. Vancouver, BC: British Columbia Office of Health Technology Assessment.
British Columbia Council on Clinical Practice Guidelines (1996). Cholesterol testing. Vancouver (BC): The Council.
Brown, J., & Kerns, V. (1985). In her prime: A new view of middle-aged women. Massachusetts: Bergin and Garvey.
Coupland, D., Lentle, B., Aldrich, J., Connell, D., & Janzen, D. (1996). Recommendations for the measurement and quantification of bone mineral density. British Columbia Medical Journal, 38(5), 265–8.
Cullen P, & Assmann, G. (1997). Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: Absolute levels or extent of lowering? The American Journal of Cardiology, 80, 1287–94.
D’Amico, A.V., Chen, M.H., Roehl, K.A., & Catalona, W. (2004). Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. New England Journal of Medicine, 351(2), 125–35.
Featherstone, M., & Hepworth, M. (1991). The mask of ageing and the postmodern life course. In M. Featherstone, M. Hepworth, & B.S Turner (Eds.), The body: Social process and cultural theory (pp. 371–389). London: Sage.
Gifford, S. (1986). The meaning of lumps: A case study of the ambiguities of risk. In C.R. Janes, R. Stall, & S.M. Gifford (Eds.), Anthropology and epidemiology: Interdisciplinary approaches to the study of health and disease (pp. 213–246). Dordrecht: Reidel.
Goffman, E. (1963). Stigma: Notes on the management of spoiled identity. Englewood Cliffs, NJ: Prentice-Hall.
Green, C.J., Hadom, D., Bassett, K., & Kazanjian, A. (1992, September). Prostate specific antigen in the early detection of prostate cancer. Vancouver, BC: British Columbia Office of Health Technology Assessment.
Green, C.J., Bassett, K., Foerster, V., & Kazanjian, A. (1997). Bone mineral density testing: Does the evidence support its selective use in well women? Vancouver, BC: British Columbia Office of Health Technology Assessment.
Green, C.J., Gallagher, R.P., & Kazanjian, A. (1999). A population-based study of the relationship between prostate specific antigen testing utilization rates and patterns of prostate cancer incidence and mortality. Vancouver, BC: British Columbia Office of Health Technology Assessment.
Grundy, S.M. (1998). Statin trails and goals for cholesterol lowering therapy. Circulation, 97, 1436–9.
Hailey, D., Sampietro-Colom, L., Marshall, D., Rico, P., Granados, A., Asua, J., et al. (1996). Statement of findings. INAHATA project on the effectiveness of bone density measurement and associated treatments for prevention of fractures. Edmonton, AB: Alberta Heritage Foundation for Medical Research.
Haraway, D. (1990). A manifesto for cyborgs: Science, technology, and socialist feminism in the 1980s. In L.J. Nicholson (Ed.), Feminism/Postmodernism (pp. 65–107). London: Routledge.
Health Services Utilization and Research Commission. (1995). Cholesterol testing and treatment guidelines. Saskatoon, SK: The Commission.
Hubbard, R. (1990). The politics of women’s biology. New Brunswick: Rutgers University Press.
Kaufert, P. (1998). Menopause as process or event: The creation of definitions in biomedicine. In M. Lock & D. Gordon (Eds.), Biomedicine examined (pp. 341–49). Dordrecht/Boston/London: Kluwer.
Kaufert, P. (1982). Myth and the menopause. Sociology of Health and Illness, 4, 141–66.
Kaufert, P., & Gilbert, P. (1986). Women, menopause, and medicalization. Culture, Medicine and Psychiatry, 10, 7–21.
Kazanjian, A., Cardiff, K., & Pagliccia, N. (1995). Design and development of a conceptual and quantitative framework for health technology decisions: A multi-project compendium of research underway. British Columbia Office of Health Technology Assessment.
Koenig, B. (1998). The technological imperative in medical practice: The social creation of a “routine” treatment. In M. Lock & D. Gordon (Eds.), Biomedicine examined (pp. 465–496). Dordrecht/Boston/London: Kluwer.
Kunisch, J.R. (1989). Electronic fetal monitors: Marketing forces and the resulting controversy. In K. S. Ratcliffe (Ed.), Healing technology: Feminist perspectives (pp. 41–60). Ann Arbor: University of Michigan Press.
Lock, M. (1993). Encounters with aging: Mythologies of menopause in Japan and North America. Berkeley and Los Angeles: University of California Press.
Lock, M. (1996, November). Social and cultural issues in connection with breast cancer testing and screening. Genetic testing for breast cancer susceptibility: The science, the ethics, the future. Paper presented at International Bioethics Conference, San Francisco.
Logan, A.G. (1994). Lowering the blood total cholesterol level to prevent coronary heart disease. Canadian Task Force on Periodic Health Examination. Canadian guide to preventive health. Ottawa, ON. Canada Communication Group.
Marshall D., Sheldon T.A., & Jonsson, E. (1997). Recommendations for the application of bone density measurement: What can you believe? International Journal of Technology Assessment in Health Care, 13(3), 411–19.
Marshall, K. (1996). Prevention. How much harm? How much benefit? Physical, psychological and social harm. Canadian Medical Association Journal, 155(2), 169–176.
Martin, E. (1991). The egg and the sperm: How science has constructed a romance based on male and female roles. Signs, 16(3), 485–501.
McKinlay, S., Brambilla, D., & Posner, J. (1992). The normal menopausal transition. Human Biology, 4, 37–46.
Mintzes, B. (1998). Blurring the boundaries: New trends in drug promotion. Health Action International-Europe.
Nelkin, D. (1996). The social dynamics of genetic testing: The case of Fragile-X. Medical Anthropology Quarterly, 10(4), 537–550.
Parsons, T. (1967). The structure of social action: a study in social theory with special reference to a group of recent European writers (2nd ed.). New York: Free Press; London: Collier-Macmillan.
Posner, T. (1991). What’s in a smear? Cervical screening, medical signs and metaphors. Science as Culture, 2(2), 167–87.
Rapp, R. (1995). Real time fetus: The role of the sonogram in the age of mechanical reproduction. In G.L. Downey, J. Dumit & S. Traweek (Eds.), Cyborgs and citadels: Anthropological interventions in the borderlands of technoscience (pp. 32–64). Seattle: University of Washington Press.
Ringertz, H., Marshall D., Johansson C., Johnell O., Kullenberg R.J., Ljunghall S. & et al. (1997). Bone density measurement: A systematic review. A report from SBU, The Swedish Council on Technology Assessment in Health Care. Journal of Internal Medicine, 241(suppl 739):i–iii, 1–60.
Rosengren, A. (1998). Cholesterol: How low is low enough? Reaching target levels may be better than relative reductions. British Medical Journal, 317, 426–7.
Savoie I., Bassett K., & Kazanjian, A. (1997, August). Supporting clinical practice guidelines development: An appraisal of existing cholesterol testing guidelines. Vancouver, BC: BC Office of Health Technology Assessment.
Savoie I., Kazanjian, A. (1999). Will it change patient management? What we really get from cholesterol testing. Vancouver, BC: BC Office of Health Technology Assessment.
Shiva, V., & Moser, I. (1995). Biopolitics: A feminist and ecological reader on biotechnology. London; Atlantic Highlands.
Skrabanek, P. (1985). False premises and false promises of breast cancer screening. The Lancet, 2, 316–320.
Strother Ratcliffe, K. (1989). Health technologies for women: Whose health? Whose technology? In K. S. Ratcliffe (Ed.), Healing technology: Feminist perspectives (pp. 173–198). Ann Arbor: University of Michigan Press.
Wald N.J., Law, M, Watt H.C., Wu,T, Bailey, A, Johnson, A.M., & et al. (1994). Apolipoproteins and ischemic heart disease: Implications for screening. The Lancet, 343, 75–79.
Whatley, M.H., & Worcester, N. (1989). The role of technology in the co-optation of the women’s health movement: The cases of osteoporosis and breast cancer. In K. S. Ratcliffe (Ed.), Healing technology: Feminist perspectives (pp. 199–220). Ann Arbor: University of Michigan Press.
WHO Study Group. (1994). Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva, Switzerland: World Health Organization.
Working Group on Hypercholesterolemia and Other Dyslipidemias. (1997, March). Detection and management of hypercholesterolemia (Interim report).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Kazanjian, A. (2005). Critical Inquiries on Technology Utilization. In: Gunn, S.W.A., Mansourian, P.B., Davies, A.M., Piel, A., Sayers, B.M. (eds) Understanding the Global Dimensions of Health. Springer, Boston, MA. https://doi.org/10.1007/0-387-24103-5_9
Download citation
DOI: https://doi.org/10.1007/0-387-24103-5_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-24102-9
Online ISBN: 978-0-387-24103-6
eBook Packages: MedicineMedicine (R0)